SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Al Hashmi S.)
 

Search: WFRF:(Al Hashmi S.) > Allogeneic Transpla...

  • Metheny, LelandUniv Hosp Cleveland Med Ctr, Seidman Canc Ctr, 11100 Euclid Ave, Cleveland, OH 44122 USA. (author)

Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults

  • Article/chapterEnglish2021

Publisher, publication year, extent ...

  • Elsevier,2021
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-460102
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-460102URI
  • https://doi.org/10.1016/j.jtct.2021.08.010DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:148204000URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Patients who develop therapy-related myeloid neoplasm, either myelodysplastic syndrome (t-MDS) or acute myelogenous leukemia (t-AML), have a poor prognosis. An earlier Center for International Blood and Marrow Transplant Research (CIBMTR) analysis of 868 allogeneic hematopoietic cell transplantations (allo-HCTs) performed between 1990 and 2004 showed a 5-year overall survival (OS) and disease-free survival (DFS) of 22% and 21%, respectively. Modern supportive care, graft-versus-host disease prophylaxis, and reduced-intensity conditioning (RIC) regimens have led to improved outcomes. Therefore, the CIBMTR analyzed 1531 allo-HCTs performed in adults with t-MDS (n = 759) or t-AML (n = 772) between and 2000 and 2014. The median age was 59 years (range, 18 to 74 years) for the patients with t-MDS and 52 years (range, 18 to 77 years) for those with tAML. Twenty-four percent of patients with t-MDS and 11% of those with t-AML had undergone a previous autologous (auto-) HCT. A myeloablative conditioning (MAC) regimen was used in 49% of patients with t-MDS and 61% of patients with t-AML. Nonrelapse mortality at 5 years was 34% (95% confidence interval [CI], 30% to 37%) for patients with t-MDS and 34% (95% CI, 30% to 37%) for those with t-AML. Relapse rates at 5 years in the 2 groups were 46% (95% CI, 43% to 50%) and 43% (95% CI, 40% to 47%). Five-year OS and DFS were 27% (95% CI, 23% to 31%) and 19% (95% CI, 16% to 23%), respectively, for patients with t-MDS and 25% (95% CI, 22% to 28%) and 23% (95% CI, 20% to 26%), respectively, for those with t-AML. In multivariate analysis, OS and DFS were significantly better in young patients with low-risk t-MDS and those with t-AML undergoing HCT with MAC while in first complete remission, but worse for those with previous auto-HCT, higher-risk cytogenetics or Revised International Prognostic Scoring System score, and a partially matched unrelated donor. Relapse remains the major cause of treatment failure, with little improvement seen over the past 2 decades. These data mandate caution when recommending allo-HCT in these conditions and indicate the need for more effective antineoplastic approaches before and after allo-HCT.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Callander, Natalie S.Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA.,Dokkyo Med Univ, Dept Hematol & Oncol, Mibu, Tochigi, Japan. (author)
  • Hall, Aric C.Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA. (author)
  • Zhang, Mei-JeiMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA. (author)
  • Bo-Subait, KhalidMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. (author)
  • Wang, Hai-LinMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. (author)
  • Agrawal, VaibhavStanford Univ, Sch Med, Dept Med, Div Blood & Marrow Transplantat, Stanford, CA 94305 USA. (author)
  • Samer Al-Homsi, A.New York Univ Langone Hlth, New York, NY USA.,Columbia Univ, Dept Med, Irving Med Ctr, Bone Marrow Transplant & Cell Therapy Program, New York, NY USA. (author)
  • Assal, AmerColumbia Univ, Dept Med, Irving Med Ctr, Bone Marrow Transplant & Cell Therapy Program, New York, NY USA.,Mayo Clin, Blood & Marrow Transplantat Program, Div Hematol Oncol, Jacksonville, FL 32224 USA.;Univ Calgary, Calgary, AB, Canada.,Univ Maryland, Greenebaum Comprehens Canc Ctr, Dept Med, Blood & Marrow Transplantat Program,Div Hematol O, Baltimore, MD 21201 USA. (author)
  • Bacher, UlrikeUniv Bern, Univ Hosp Bern, Inselspital, Dept Hematol, Bern, Switzerland. (author)
  • Beitinjaneh, AmerUniv Miami, Div Transplantat & Cellular Therapy, Miami, FL USA. (author)
  • Bejanyan, NelliH Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Minneapolis, MN USA. (author)
  • Bhatt, Vijaya RajUniv Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE USA. (author)
  • Bredeson, ChrisOttawa Hosp, Blood & Marrow Transplant Program, Ottawa, ON, Canada.;Ottawa Hosp Res Inst, Ottawa, ON, Canada. (author)
  • Byrne, MichaelVanderbilt Univ, Med Ctr, Nashville, TN USA. (author)
  • Cairo, MitchellNew York Med Coll, Dept Pediat, Div Pediat Hematol Oncol & Stem Cell Transplantat, Valhalla, NY 10595 USA. (author)
  • Cerny, JanUniv Massachusetts, Med Ctr, Dept Med, Div Hematol Oncol, Worcester, MA USA. (author)
  • DeFilipp, ZachariahMassachusetts Gen Hosp, Hematopoiet Cell Transplant & Cellular Therapy Pr, Boston, MA 02114 USA. (author)
  • Diaz Perez, Miguel AngelHosp Infantil Univ Nino Jesus, Dept Hematol Oncol, Madrid, Spain. (author)
  • Freytes, César O.Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. (author)
  • Ganguly, SiddharthaUniv Kansas Hlth Syst, Div Hematol Malignancy & Cellular Therapeut, Kansas City, KS USA. (author)
  • Grunwald, Michael R.Atrium Hlth, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA. (author)
  • Hashmi, ShahrukhMayo Clin, Dept Internal Med, Rochester, MN USA.;Sheikh Shakhbout Med City, Dept Med, Abu Dhavi, U Arab Emirates. (author)
  • Hildebrandt, Gerhard C.Univ Kentucky, Markey Canc Ctr, Lexington, KY USA. (author)
  • Inamoto, YoshihiroNatl Canc Ctr, Div Hematopoiet Stem Cell Transplantat, Tokyo, Japan. (author)
  • Kanakry, Christopher G.NCI, Expt Transplantat & Immunotherapy Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. (author)
  • Kharfan-Dabaja, Mohamed A.Mayo Clin, Blood & Marrow Transplantat Program, Div Hematol Oncol, Jacksonville, FL 32224 USA.;Univ Calgary, Calgary, AB, Canada. (author)
  • Lazarus, Hillard M.Case Western Reserve Univ, Univ Hosp Cleveland Med Ctr, Cleveland, OH 44106 USA. (author)
  • Lee, Jong WookCatholic Univ Korea, Seoul St Marys Hosp, Div Hematol, Seoul, South Korea. (author)
  • Nathan, SunitaRush Univ, Med Ctr, Sect Bone Marrow Transplant & Cell Therapy, Chicago, IL 60612 USA. (author)
  • Nishihori, TaigaH Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Minneapolis, MN USA. (author)
  • Olsson, Richard F.Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Dept Lab Med, Stockholm, Sweden(Swepub:uu)riols677 (author)
  • Ringdén, OlovKarolinska Institutet,Karolinska Inst, Translat Cell Therapy Grp, CLINTEC Clin Sci Intervent & Technol, Stockholm, Sweden. (author)
  • Rizzieri, DavidDuke Univ, Div Hematol Malignancies & Cellular Therapy, Durham, NC USA. (author)
  • Savani, Bipin N.Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA. (author)
  • Savoie, Mary Lynn (author)
  • Seo, SachikoDokkyo Med Univ, Dept Hematol & Oncol, Mibu, Tochigi, Japan.,NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA. (author)
  • van der Poel, MarjoleinMaastricht Univ, Med Ctr, Maastricht, Netherlands. (author)
  • Verdonck, Leo F.Isala Clin, Dept Hematol Oncol, Zwolle, Netherlands. (author)
  • Wagner, John L.Thomas Jefferson Univ, Dept Med Oncol, Philadelphia, PA 19107 USA. (author)
  • Yared, Jean A.Univ Maryland, Greenebaum Comprehens Canc Ctr, Dept Med, Blood & Marrow Transplantat Program,Div Hematol O, Baltimore, MD 21201 USA. (author)
  • Hourigan, Christopher S.NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA. (author)
  • Kebriaei, PartowUniv Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat, Div Canc Med, Houston, TX 77030 USA. (author)
  • Litzow, MarkMayo Clin Rochester, Div Hematol, Rochester, MN USA.;Mayo Clin Rochester, Transplant Ctr, Rochester, MN USA. (author)
  • Sandmaier, Brenda M.Univ Washington, Div Med Oncol, Seattle, WA 98195 USA.;Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA. (author)
  • Saber, WaelMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. (author)
  • Weisdorf, DanielUniv Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Box 736 UMHC, Minneapolis, MN 55455 USA. (author)
  • de Lima, MarcosUniv Hosp Case Med Ctr, Seidman Canc Ctr, Dept Med, Cleveland, OH USA. (author)
  • Freytes, EO (author)
  • Univ Hosp Cleveland Med Ctr, Seidman Canc Ctr, 11100 Euclid Ave, Cleveland, OH 44122 USA.Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA. (creator_code:org_t)

Related titles

  • In:Transplantation and Cellular Therapy: Elsevier27:11, s. 923.e1-923.e122666-63752666-6367

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view